These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 7870908)

  • 1. Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB.
    Sahakian BJ; Owen AM; Morant NJ; Eagger SA; Boddington S; Crayton L; Crockford HA; Crooks M; Hill K; Levy R
    Psychopharmacology (Berl); 1993; 110(4):395-401. PubMed ID: 7870908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tetrahydroaminoacridine (THA) in Alzheimer's disease: an assessment of attentional and mnemonic function using CANTAB.
    Sahakian BJ; Coull JT
    Acta Neurol Scand Suppl; 1993; 149():29-35. PubMed ID: 8128835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychometric discrimination of tetrahydroaminoacridine responders in Alzheimer patients.
    Alhainen K; Helkala EL; Riekkinen P
    Dementia; 1993; 4(1):54-8. PubMed ID: 8358507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrine (tetrahydroaminoacridine; THA) and lecithin in senile dementia of the Alzheimer type: a multicentre trial. Groupe Français d'Etude de la Tetrahydroaminoacridine.
    Chatellier G; Lacomblez L
    BMJ; 1990 Feb; 300(6723):495-9. PubMed ID: 2107926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontal dysfunction blocks the therapeutic effect of THA on attention in Alzheimer's disease.
    Riekkinen P; Riekkinen M; Soininen H; Kuikka J; Laakso M; Riekkinen P
    Neuroreport; 1997 May; 8(8):1845-9. PubMed ID: 9223063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
    Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
    Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of acute nicotine administration on cognitive event-related potentials in tacrine-treated and non-treated patients with Alzheimer's disease.
    Knott V; Mohr E; Mahoney C; Engeland C; Ilivitsky V
    Neuropsychobiology; 2002; 45(3):156-60. PubMed ID: 11979067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease.
    Perryman KM; Fitten LJ
    Life Sci; 1993; 53(6):479-86. PubMed ID: 8341134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tacrine treatment modifies cerebrospinal fluid neuropeptide levels in Alzheimer's disease.
    Minthon L; Edvinsson L; Gustafson L
    Dementia; 1994; 5(6):295-301. PubMed ID: 7866482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WITHDRAWN: Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measurement of cholinergic drug effects on memory in Alzheimer's disease.
    Brinkman SD; Gershon S
    Neurobiol Aging; 1983; 4(2):139-45. PubMed ID: 6355883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hippocampal atrophy, acute THA treatment and memory in Alzheimer's disease.
    Riekkinen P; Soininen H; Helkala EL; Partanen K; Laakso M; Vanhanen M; Riekkinen P
    Neuroreport; 1995 Jun; 6(9):1297-300. PubMed ID: 7669991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease and THA: a review of the cholinergic theory and of preliminary results.
    Boller F; Forette F
    Biomed Pharmacother; 1989; 43(7):487-91. PubMed ID: 2684292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of tacrine and lecithin in mild to moderate Alzheimer's disease: double blind trial.
    Maltby N; Broe GA; Creasey H; Jorm AF; Christensen H; Brooks WS
    BMJ; 1994 Apr; 308(6933):879-83. PubMed ID: 8173365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral tetrahydroaminoacridine treatment of Alzheimer's disease evaluated clinically and by regional cerebral blood flow and EEG.
    Minthon L; Gustafson L; Dalfelt G; Hagberg B; Nilsson K; Risberg J; Rosén I; Seiving B; Wendt PE
    Dementia; 1993; 4(1):32-42. PubMed ID: 8358504
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An extract of Salvia (sage) with anticholinesterase properties improves memory and attention in healthy older volunteers.
    Scholey AB; Tildesley NT; Ballard CG; Wesnes KA; Tasker A; Perry EK; Kennedy DO
    Psychopharmacology (Berl); 2008 May; 198(1):127-39. PubMed ID: 18350281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic sulpiride in young adult volunteers simulates the profile of cognitive deficits in Parkinson's disease.
    Mehta MA; Sahakian BJ; McKenna PJ; Robbins TW
    Psychopharmacology (Berl); 1999 Sep; 146(2):162-74. PubMed ID: 10525751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.
    Raskind MA; Sadowsky CH; Sigmund WR; Beitler PJ; Auster SB
    Arch Neurol; 1997 Jul; 54(7):836-40. PubMed ID: 9236571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute nicotine effects on auditory sensory memory in tacrine-treated and nontreated patients with Alzheimer's disease: an event-related potential study.
    Engeland C; Mahoney C; Mohr E; Ilivitsky V; Knott VJ
    Pharmacol Biochem Behav; 2002 May; 72(1-2):457-64. PubMed ID: 11900820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of velnacrine for the treatment of Alzheimer's disease. A double-blind, placebo-controlled study. Mentane Study Group.
    Antuono PG
    Arch Intern Med; 1995 Sep; 155(16):1766-72. PubMed ID: 7654110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.